JZL195 is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), two key enzymes involved in the breakdown of endocannabinoids. By inhibiting these enzymes, JZL195 increases levels of endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol (2-AG) in the brain and peripheral tissues. This action enhances endocannabinoid signaling, which plays a role in regulating pain, mood, inflammation, and neuroprotection. It is primarily used in preclinical research to study the effects of elevated endocannabinoid tone. Researchers use JZL195 to investigate potential therapeutic strategies for conditions such as chronic pain, anxiety, depression, and neurodegenerative diseases like Parkinson’s and Alzheimer’s. Its ability to simultaneously target FAAH and MAGL makes it a valuable tool for understanding the interplay between different endocannabinoids in physiological and pathological processes. Due to its research-focused use, JZ195 is not used clinically but remains important in advancing knowledge of the endocannabinoid system and in the development of future therapeutics targeting this pathway.